Aaron Hartman, MDFunctional Medicine Specialist | Clinical Researcher

Dr

19 Aug 2024 · 1 min

Watch on YouTube

0:32

Aaron Hartman, MD (speaker) discusses the APOE genotype—particularly APOE4—and its clinical implications. He contrasts past pessimism (that knowing APOE4 status was futile) with current practice in some Alzheimer’s clinics that measure APOE4 and pursue early-life interventions (lifestyle changes, supplements, and prescription medicines) to reduce Alzheimer’s risk.

Chapters

APOE gives you a lot of stuff. Now the people say, oh, my God, you don't want to know you're going to dementia because there's nothing you can do about it. That was true about 15, 20 years ago. But I can tell you there have been Alzheimer's disease clinics that for 20 years have been measuring the APOE 4 genotype because they believe there's a lot of stuff you can do if you get the E4s early in life, with lifestyle and even certain supplemental, even prescription medicine nowadays, that would prevent the development of Alzheimer's disease.